Doctorate in Business Administration (DBA) from Paris School of Business

One of China's 30 Most Influential Investors, Honorary President of the Hong Kong Association of Pharmaceutical Innovation, Founding Member of the Investment Committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), Member of the BayHelix Group, and Distinguished Lecturer at Duke Kunshan University.

With over a decade of experience in the investment industry, he has focused on the biopharmaceutical sector, contributing to the advancement of the pharmaceutical industry. He has led investments in Heyuan Biosciences, Chipscreen Biosciences, Ascentage Pharma, Frontier Biotechnologies, Genuine Biotech, Qyuns Therapeutics, and others.

His accolades include:

• CHC · Top 50 Most Influential Investors of the Year

• FOF Weekly · Top 20 Best Healthcare Investors of 2023

• CHC · Top 50 Most Influential Investors of 2022

• ChinaVenture · Top 100 Chinese Best Venture Capitalists of 2021

• Best Investor in the Medical and Health Industry 2020

• China Financial Person of the Year Top 5 2019

• Bachelor of Arts in Economics, University of California, San Diego (UCSD)

• Member of the Inaugural Cohort of Young Investors of H50 (China Healthcare Investment H50)
  2023 Forbes China · Top 100 Young Returnee Elites
  2025 Fortune China · 40 Under 40 – Most Promising Business Elites
  Consecutive Honoree, U40 Young Elite List
  40 Under 40 – Best Direct Investment Fund Young Investors
  2022 Supernova · Top 50
  Young Investor in Healthcare

• Initiated and deeply participated in investments in star projects including OBiO Technology, Asieris Pharmaceuticals, Insight Lifetech, and Harbour BioMed

• Previously served in the Asset Management Department of China International Capital Corporation (CICC)

Hong Kong SFC Type 9 Responsible Officer (RO)

Master of Pharmacy (M.Pharm.)

China Pharmaceutical University

Former Roles:

Director of Pharmaceutical & Healthcare Business, Strategic Management Department, China Resources Group

General Manager of Investment & Development, China Resources Life Sciences Group

Production & Operations Director, GlaxoSmithKline (GSK)

• Ph.D., Zhejiang University; Postdoctoral Fellow, Baylor College of Medicine; Adjunct Professor, Zhejiang University School of Medicine

• Principal Investigator (PI) at an independent laboratory in the United States; Supervisor for doctoral students and postdoctoral fellows; Recipient of multiple research grants, including the R01 grant from the National Institutes of Health (NIH)

• A decade of experience in the pharmaceutical industry; previously worked at Lexicon Pharmaceuticals (USA), Hisun Pharma, and others; contributed to the market approval or clinical trial advancement of multiple products

• Former Partner at Yingke Capital; full-spectrum coverage of pharmaceuticals, medical devices, IVD, and CXO; invested in over 30 portfolio companies

Bachelor of Arts in Economics

University of Washington, U.S.A.

Ten years of experience in financial management and corporate operations.

Former Role:

Group Finance Department, Huawei Technologies Co., Ltd. — with deep expertise in financial coordination, internal control, and organizational management.

Current Role:

Member of the Management Decision Committee, with overall responsibility for corporate financial management, human resources & administration, and digital transformation initiatives. Committed to advancing the standardization of corporate governance systems and enhancing organizational effectiveness.

Bachelor's degree in Pharmacy from Shanghai Jiao Tong University and Master's degree in Finance from Durham University, UK, with a multidisciplinary background. Five years of investment experience, specializing in medical devices and new materials. Successfully exited 4 investments, including 2 IPO projects.